INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSKPRNewsWire • 09/03/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKGlobeNewsWire • 09/02/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKGlobeNewsWire • 08/29/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSKGlobeNewsWire • 08/21/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKGlobeNewsWire • 08/17/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKGlobeNewsWire • 08/13/25
GSK secures $370 million settlement and future royalties in CureVac mRNA patent disputeProactive Investors • 08/08/25
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challengesWSJ • 08/01/25
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook RaiseZacks Investment Research • 07/30/25
GSK may have numbers may have been flattered by order timing, says bankProactive Investors • 07/30/25